Source / episode info
- **Episode:**42
- **Title:**Divine Intervention Episode 42 – Pharmacology of The Eye.
- **Published:**2018-08-03
- Source:Episode page
One-liner
This episode provides a comprehensive review of ocular pharmacology, covering the differentiation between dry and wet AMD (VEGF pathway), glaucoma pathophysiology (production vs. drainage issues), and the mechanisms of action for key drug classes including beta-blockers, alpha-2 agonists, carbonic anhydrase inhibitors, and prostaglandin analogs.
High-yield summary
- Macular Degeneration: Central vision loss precedes peripheral vision loss. Wet AMD is caused by fragile neovascularization (choroidal blood vessels) stimulated by VEGF; treatment requires anti-VEGF monoclonal antibodies (Bevacizumab, Ranibizumab) via intraocular injection.
- Glaucoma Pathophysiology: Open-angle glaucoma results from either excessive aqueous humor production or impaired drainage. The angle between the cornea and lens is critical for drainage through the canal of Schlemm.
- Carbonic Anhydrase Inhibitors (CAIs): Drugs like Acetazolamide decrease aqueous humor production by inhibiting CA in the ciliary body, making it useful for glaucoma and Idiopathic Intracranial Hypertension (IIH).
- Drug Mechanisms: Glaucoma medications target multiple pathways: _2-blockers (Timolol) reduce production; _2-agonists (Brimonidine) decrease sympathetic outflow, thereby reducing aqueous humor secretion.
- Systemic CAI Effects: Systemically, Acetazolamide causes a Type 2 Renal Tubular Acidosis (RTA) due to proximal bicarbonate wasting, leading to metabolic acidosis and hypochloremia; it is also used for altitude sickness and IIH.
- Prostaglandin Analogs: These drugs promote uveoscleral outflow by dilating the canal of Schlemm but carry risks of eyelash thickening and eyelid discoloration.
Learning objectives
- Differentiate the clinical presentation and pathophysiology of dry versus wet Age-Related Macular Degeneration (AMD).
- Identify the mechanism and indications for anti-VEGF therapies in treating AMD.
- Describe the anatomical structures of the eye, specifically the anterior/posterior segments and the flow of aqueous humor.
- Correlate glaucoma risk factors (e.g., steroids) with potential complications and prophylactic treatments.
- Explain the mechanisms of action and clinical uses of key ocular medications: beta-blockers, alpha-2 agonists, CAIs, and prostaglandin analogs.